Pharmaceuticals South Africa

South Africa Immunoglobulin Therapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

South Africa Immunoglobulin Therapy Market Industry Trends and Forecast to 2034: Segmented by (Route, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

South Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $98.6 Mn Placeholder estimate
Estimate 2025 $106.9 Mn 0.7% of the global market
Projected 2034 $221.0 Mn 106.7% Adds $114.1 Mn over 9 forecast years
CAGR 2025–2034 8.4% Faster than 39% of 180 Pharmaceuticals markets here
Key players 5
  • South Africa is 0.67% of the global market.
  • In Africa, the largest is South Africa (this report) at $106.9 Mn.
  • Fastest growing: Egypt at 8.8% a year.
  • South Africa ranks 1st of 3 by size in Africa.

Market size projection

South Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$114.1 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Immunoglobulin Therapy Market market size by year, South Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $98.6 Mn — —
2025 (base) $106.9 Mn +$8.3 Mn —
2026 (forecast) $115.9 Mn +$9.0 Mn +8.4%
2027 (forecast) $125.6 Mn +$9.7 Mn +17.5%
2028 (forecast) $136.2 Mn +$10.6 Mn +27.4%
2029 (forecast) $147.6 Mn +$11.4 Mn +38.1%
2030 (forecast) $160.0 Mn +$12.4 Mn +49.7%
2031 (forecast) $173.5 Mn +$13.4 Mn +62.2%
2032 (forecast) $188.1 Mn +$14.6 Mn +75.9%
2033 (forecast) $203.9 Mn +$15.8 Mn +90.6%
2034 (forecast) $221.0 Mn +$17.1 Mn +106.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

South Africa Immunoglobulin Therapy Market Analysis at a glance
Market size, 2025$106.9 Mn placeholder estimate
Forecast, 2034$221.0 Mn placeholder estimate
Growth (CAGR), 2025–20348.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsRoute, indication and end user (see all)
Key playersCSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma, Kedrion Biopharma (see all)
Regulator in South AfricaSAHPRASource: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
Active clinical trials13 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The South Africa Immunoglobulin Therapy Market Analysis Executive Summary

Immunoglobulin therapy gives antibodies from donated blood to treat immune deficiencies and some nerve and blood diseases.

Key segments of the immunoglobulin Therapy market include route (Intravenous and Subcutaneous) and indication (Primary Immunodeficiency, CIDP and Immune Thrombocytopenia).

Bar chart: South Africa Immunoglobulin Therapy market size, 2024–2034, placeholder estimates. $98.6 Mn in 2024, $106.9 Mn in 2025 and $221.0 Mn in 2034, 8.4% CAGR.
South Africa Immunoglobulin Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

South Africa Immunoglobulin Therapy Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the immunoglobulin Therapy market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the immunoglobulin Therapy market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the immunoglobulin Therapy market.

Competitive Landscape for Immunoglobulin Therapy Market in South Africa

The immunoglobulin Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Immunoglobulin Therapy Market in South Africa

Immunoglobulin Therapy in South Africa: rules, payment and research

The South African Health Products Regulatory Authority (SAHPRA) registers medicines.⁠[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.⁠[2] ClinicalTrials.gov lists 13 studies on Immunoglobulin Therapy that are recruiting, active or about to start in South Africa.⁠[3]

[1] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[2] National Department of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for immunoglobulin Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Immunoglobulin Therapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Immunoglobulin Therapy in context

South Africa compared

  • Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Immunoglobulin Therapy market in South Africa?
Placeholder estimate: about $106.9 Mn in 2025, rising to about $221.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Immunoglobulin Therapy market in South Africa growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Immunoglobulin Therapy market report cover?
The report splits the market by route (Intravenous, Subcutaneous), indication (Primary Immunodeficiency, CIDP, Immune Thrombocytopenia, Others) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Immunoglobulin Therapy market?
Key players include CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma and Kedrion Biopharma.
What is driving the Immunoglobulin Therapy market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the immunoglobulin Therapy market. Biosimilars are widening access.
Who regulates Immunoglobulin Therapy in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) registers medicines. Source: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
How is healthcare paid for in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on Immunoglobulin Therapy are running in South Africa?
13 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
How much research is published on Immunoglobulin Therapy?
PubMed lists 769 papers on Immunoglobulin Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in South Africa

See all

Related on biologics and biosimilars

See the topic